Return to GVPedia

Wednesday 23 May 2012

You are here:

100 Years

 

GSK has had a presence in South Africa since 1902 .In addition to marketing and sales operations, the company has manufactured Consumer healthcare and Pharmaceutical products for the last 60 years in a variety of different locations which were consolidated into a single factory in Cape Town in 2002.

Contact

Links

Social Bookmarking

GlaxoSmithKline, South Africa

(100 years in South Africa)

Pharmaceuticals
• GSK South Africa is ranked 9th in the pharmaceuticals industry
• GSK is ranked 2nd in the vaccines market with a value market share of 29.5%
• Key therapeutic areas: Respiratory, vaccines, central nervous system (CNS), metabolic, anti infectives, anaesthesia

 

Consumer Healthcare
• GSK is ranked 2nd within the South African Consumer Healthcare industry, with strong No. 1 and No. 2 positions in both Oral Healthcare and OTC products.
• Major Consumer Healthcare Products are Grand-Pa, Aquafresh, Eno, MedLemon, Borstol, Lucozade, Scotts and Sensodyne.

 

Global Manufacturing & Supply (GMS)
• The South African factory is located in Cape Town, manufacturing mainly for the local markets, both pharmaceutical and consumer healthcare products, and currently exports to 34 markets in Africa, Middle East and Hong Kong. In addition, it manufactures Albendazole tablets for the GSK donation programme to eliminate lymphatic filariasis. The total manufacturing investment is presently £55 million and the company is continuing to invest in expansion and replacement at a level of around £5 million per annum.

Access Programme for HIV/AIDS

 

In 2001 the global GlaxoSmithKline group announced its commitment to making medicines for HIV/AIDS and malaria available at not-for-profit preferential pricing in 63 countries – including the Least Developed Countries and sub-Saharan Africa. This offer extends to governments, non-government organizations (NGOs) and international aid groups and in sub- Saharan Africa to employers as well.

 

To date GlaxoSmithKline has granted six (6) voluntary licenses to generic manufactures to produce its antiretrovirals (ARV’s) in South Africa.

Corporate Social Investment (CSI)

Partnering with communities throughout South Africa

 

Local community partnerships are in place, particularly in the rural areas of the country. The main areas covered are: HIV, education and primary healthcare. The company has, since the merger, invested more than R12 million in impoverished communities.

 

Community projects also involve working closely with the provincial Departments of Health to ensure that the company is aligned to government priorities.

• HIV/AIDS, children’s health, primary health care, community clinics.
• Some of the community projects include HIV/AIDS, Mental Health, School Soccer Cup (Aquafresh), Winter Knitting Project (MedLemon), Safer Taxis for South Africa Campaign (GrandPa).

 

Research & Development (R&D)

• There are currently 15 ongoing phase I to III clinical trials being conducted in respiratory, oncology, diabetes, muscular and bone disorders and psychiatric disorders.

• There are partnerships with the World Health Organization (WHO) in terms of various vaccine development programmes e.g. Rotavirus vaccine (Rotavirus collaboration is in South and Sub-Saharan Africa) and Malaria vaccine (collaboration is in Mozambique).

• GlaxoSmithKline is a pharmaceutical company that is highly committed to the research of finding BOTH new medicines and vaccines for the treatment and prevention of HIV/AIDS, Tuberculosis and Malaria – the three diseases identified as priority by the World Health Organization (WHO).

 

GlaxoSmithKline’s Mission
“Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer.”

 

Footer Information:

Home